Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Raw Materials (2018 - 2022)

AVITA Medical's Raw Materials history spans 5 years, with the latest figure at $1.1 million for Q4 2022.

  • For Q4 2022, Raw Materials fell 7.45% year-over-year to $1.1 million; the TTM value through Dec 2022 reached $1.1 million, down 7.45%, while the annual FY2022 figure was $1.1 million, N/A changed from the prior year.
  • Raw Materials reached $1.1 million in Q4 2022 per RCEL's latest filing, down from $1.2 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.2 million in Q4 2021 to a low of $589691.6 in Q2 2018.
  • Average Raw Materials over 5 years is $913402.2, with a median of $964500.0 recorded in 2020.
  • Peak YoY movement for Raw Materials: soared 55.57% in 2020, then fell 7.45% in 2022.
  • A 5-year view of Raw Materials shows it stood at $589691.6 in 2018, then increased by 3.23% to $608721.6 in 2019, then skyrocketed by 55.57% to $947000.0 in 2020, then rose by 29.04% to $1.2 million in 2021, then decreased by 7.45% to $1.1 million in 2022.
  • Per Business Quant, the three most recent readings for RCEL's Raw Materials are $1.1 million (Q4 2022), $1.2 million (Q4 2021), and $982000.0 (Q2 2021).